http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 02 Mar 2026 16:21:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++ALLURION+TECHNOLOGIES%2C+++++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26092493.html si-local-file:///var/storage/secattach/20260302/26092493.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++ALLURION+TECHNOLOGIES%2C+++++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26092493.html Mon, 02 Mar 2026 16:21:00 -0500 ALUR O.52535872 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++ALLURION+TECHNOLOGIES%2C+++++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26092493.html si-local-file:///var/storage/secattach/20260302/26092493.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++ALLURION+TECHNOLOGIES%2C+++++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26092493.html Mon, 02 Mar 2026 16:21:00 -0500 ALUR O.52535872 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ALLURION+TECHNOLOGIES%2C++++For%3A+Mar+02/26088298.html si-local-file:///var/storage/secattach/20260302/26088298.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ALLURION+TECHNOLOGIES%2C++++For%3A+Mar+02/26088298.html Mon, 02 Mar 2026 09:19:00 -0500 ALUR O.52535872 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ALLURION+TECHNOLOGIES%2C++++For%3A+Mar+02/26088298.html si-local-file:///var/storage/secattach/20260302/26088298.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ALLURION+TECHNOLOGIES%2C++++For%3A+Mar+02/26088298.html Mon, 02 Mar 2026 09:19:00 -0500 ALUR O.52535872 http://www.streetinsider.com/Corporate+News/Allurion+to+appeal+NYSE+delisting+notice%2C+plans+compliance+recovery/26088130.html <p>Allurion Technologies Inc. (NYSE: ALUR) received a delisting notice from the New York Stock Exchange for failing to maintain required financial thresholds under Section 802.01B of the Listed Company Manual, according to a company statement.</p><p>The NYSE requires listed companies to maintain either $50 million in stockholders' equity or $50 million in total market capitalization on a 30-trading day average basis. Allurion did not meet these requirements.</p><p>The company plans to appeal the determination and expects its common stock to continue trading on the NYSE during the appeal process. Allurion has the right to request a review by a Committee of the http://www.streetinsider.com/Corporate+News/Allurion+to+appeal+NYSE+delisting+notice%2C+plans+compliance+recovery/26088130.html Mon, 02 Mar 2026 09:03:18 -0500 ALUR http://www.streetinsider.com/Press+Releases/Allurion+Intends+to+Appeal+NYSE+Notice+of+Delisting%2C+Execute+Plan+to+Regain+Compliance%2C+and+Expects+to+Continue+Trading+on+NYSE/26088030.html <p class="bwalignc"> <i>Company’s recent FDA approval catalyzes plan to regain compliance with listing requirements of NYSE or another exchange; shares of common stock expected to continue trading on NYSE during appeal process</i> </p> <p> NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) that it intends to initiate delisting proceedings against Allurion after the Company was unable to demonstrate that it had regained compliance with Section 802.01B of the Listed Company Manual requiring listed companies to maintain either (i) at least $50 million http://www.streetinsider.com/Press+Releases/Allurion+Intends+to+Appeal+NYSE+Notice+of+Delisting%2C+Execute+Plan+to+Regain+Compliance%2C+and+Expects+to+Continue+Trading+on+NYSE/26088030.html Mon, 02 Mar 2026 09:00:00 -0500 ALUR O.52535872 http://www.streetinsider.com/Press+Releases/Allurion+Intends+to+Appeal+NYSE+Notice+of+Delisting%2C+Execute+Plan+to+Regain+Compliance%2C+and+Expects+to+Continue+Trading+on+NYSE/26088030.html <p class="bwalignc"> <i>Company’s recent FDA approval catalyzes plan to regain compliance with listing requirements of NYSE or another exchange; shares of common stock expected to continue trading on NYSE during appeal process</i> </p> <p> NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) that it intends to initiate delisting proceedings against Allurion after the Company was unable to demonstrate that it had regained compliance with Section 802.01B of the Listed Company Manual requiring listed companies to maintain either (i) at least $50 million http://www.streetinsider.com/Press+Releases/Allurion+Intends+to+Appeal+NYSE+Notice+of+Delisting%2C+Execute+Plan+to+Regain+Compliance%2C+and+Expects+to+Continue+Trading+on+NYSE/26088030.html Mon, 02 Mar 2026 09:00:00 -0500 ALUR O.52535872 http://www.streetinsider.com/Business+Wire/Allurion+Intends+to+Appeal+NYSE+Notice+of+Delisting%2C+Execute+Plan+to+Regain+Compliance%2C+and+Expects+to+Continue+Trading+on+NYSE/26088030.html <p class="bwalignc"> <i>Company’s recent FDA approval catalyzes plan to regain compliance with listing requirements of NYSE or another exchange; shares of common stock expected to continue trading on NYSE during appeal process</i> </p> <p> NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) that it intends to initiate delisting proceedings against Allurion after the Company was unable to demonstrate that it had regained compliance with Section 802.01B of the Listed Company Manual requiring listed companies to maintain either (i) at least $50 million http://www.streetinsider.com/Business+Wire/Allurion+Intends+to+Appeal+NYSE+Notice+of+Delisting%2C+Execute+Plan+to+Regain+Compliance%2C+and+Expects+to+Continue+Trading+on+NYSE/26088030.html Mon, 02 Mar 2026 09:00:00 -0500 ALUR O.52535872 http://www.streetinsider.com/Business+Wire/Allurion+Intends+to+Appeal+NYSE+Notice+of+Delisting%2C+Execute+Plan+to+Regain+Compliance%2C+and+Expects+to+Continue+Trading+on+NYSE/26088030.html <p class="bwalignc"> <i>Company’s recent FDA approval catalyzes plan to regain compliance with listing requirements of NYSE or another exchange; shares of common stock expected to continue trading on NYSE during appeal process</i> </p> <p> NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) that it intends to initiate delisting proceedings against Allurion after the Company was unable to demonstrate that it had regained compliance with Section 802.01B of the Listed Company Manual requiring listed companies to maintain either (i) at least $50 million http://www.streetinsider.com/Business+Wire/Allurion+Intends+to+Appeal+NYSE+Notice+of+Delisting%2C+Execute+Plan+to+Regain+Compliance%2C+and+Expects+to+Continue+Trading+on+NYSE/26088030.html Mon, 02 Mar 2026 09:00:00 -0500 ALUR O.52535872 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ALLURION+TECHNOLOGIES%2C++++For%3A+Feb+24/26055851.html si-local-file:///var/storage/secattach/20260225/26055851.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ALLURION+TECHNOLOGIES%2C++++For%3A+Feb+24/26055851.html Wed, 25 Feb 2026 08:30:00 -0500 ALUR O.52535872 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ALLURION+TECHNOLOGIES%2C++++For%3A+Feb+24/26055851.html si-local-file:///var/storage/secattach/20260225/26055851.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ALLURION+TECHNOLOGIES%2C++++For%3A+Feb+24/26055851.html Wed, 25 Feb 2026 08:30:00 -0500 ALUR O.52535872 http://www.streetinsider.com/Press+Releases/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html <p> NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Warrants” and together with the January 2025 Warrants and the February 2025 Warrants, the “Existing Warrants”), at a reduced exercise price of $1.15 per http://www.streetinsider.com/Press+Releases/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html Tue, 24 Feb 2026 09:15:00 -0500 A.01857600 ALUR O.00080482 O.52535872 http://www.streetinsider.com/Press+Releases/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html <p> NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Warrants” and together with the January 2025 Warrants and the February 2025 Warrants, the “Existing Warrants”), at a reduced exercise price of $1.15 per http://www.streetinsider.com/Press+Releases/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html Tue, 24 Feb 2026 09:15:00 -0500 A.01857600 ALUR O.00080482 O.52535872 http://www.streetinsider.com/Press+Releases/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html <p> NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Warrants” and together with the January 2025 Warrants and the February 2025 Warrants, the “Existing Warrants”), at a reduced exercise price of $1.15 per http://www.streetinsider.com/Press+Releases/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html Tue, 24 Feb 2026 09:15:00 -0500 A.01857600 ALUR O.00080482 O.52535872 http://www.streetinsider.com/Press+Releases/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html <p> NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Warrants” and together with the January 2025 Warrants and the February 2025 Warrants, the “Existing Warrants”), at a reduced exercise price of $1.15 per http://www.streetinsider.com/Press+Releases/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html Tue, 24 Feb 2026 09:15:00 -0500 A.01857600 ALUR O.00080482 O.52535872 http://www.streetinsider.com/Business+Wire/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html <p> NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Warrants” and together with the January 2025 Warrants and the February 2025 Warrants, the “Existing Warrants”), at a reduced exercise price of $1.15 per http://www.streetinsider.com/Business+Wire/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html Tue, 24 Feb 2026 09:15:00 -0500 A.01857600 ALUR O.00080482 O.52535872 http://www.streetinsider.com/Business+Wire/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html <p> NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Warrants” and together with the January 2025 Warrants and the February 2025 Warrants, the “Existing Warrants”), at a reduced exercise price of $1.15 per http://www.streetinsider.com/Business+Wire/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html Tue, 24 Feb 2026 09:15:00 -0500 A.01857600 ALUR O.00080482 O.52535872 http://www.streetinsider.com/Business+Wire/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html <p> NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Warrants” and together with the January 2025 Warrants and the February 2025 Warrants, the “Existing Warrants”), at a reduced exercise price of $1.15 per http://www.streetinsider.com/Business+Wire/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html Tue, 24 Feb 2026 09:15:00 -0500 A.01857600 ALUR O.00080482 O.52535872 http://www.streetinsider.com/Business+Wire/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html <p> NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Warrants” and together with the January 2025 Warrants and the February 2025 Warrants, the “Existing Warrants”), at a reduced exercise price of $1.15 per http://www.streetinsider.com/Business+Wire/Allurion+Announces+Exercise+of+Warrants+for+%243.0+Million+in+Gross+Proceeds/26048131.html Tue, 24 Feb 2026 09:15:00 -0500 A.01857600 ALUR O.00080482 O.52535872 http://www.streetinsider.com/Upgrades/Chardan+Capital+Markets+Upgrades+Allurion+Technologies+%28ALUR%29+to+Buy/26046800.html (Updated - February 24, 2026 7:39 AM EST) <p>Chardan Capital Markets analyst Keay Nakae upgraded Allurion Technologies (NYSE: ALUR) from Neutral to Buy with a price target of $3.00.</p><p>The analyst comments "ALUR: Co. Obtains FDA Approval of Gastric Balloon. Upgrading to BUY, PT $3 The company has announced that it has obtained FDA approval for its Gastric Balloon System, featuring the Allurion Smart Capsule. We believe that FDA approval significantly increases the options available to Management going forward to support execution of its business plan. Hence, we upgrade our rating from Neutral to Buy, and establish a new price target of http://www.streetinsider.com/Upgrades/Chardan+Capital+Markets+Upgrades+Allurion+Technologies+%28ALUR%29+to+Buy/26046800.html Tue, 24 Feb 2026 07:39:20 -0500 ALUR http://www.streetinsider.com/Analyst+Comments/Chardan+Capital+Markets+Upgrades+Allurion+Technologies+%28ALUR%29+to+Buy/26046800.html (Updated - February 24, 2026 7:39 AM EST) <p>Chardan Capital Markets analyst Keay Nakae upgraded Allurion Technologies (NYSE: ALUR) from Neutral to Buy with a price target of $3.00.</p><p>The analyst comments "ALUR: Co. Obtains FDA Approval of Gastric Balloon. Upgrading to BUY, PT $3 The company has announced that it has obtained FDA approval for its Gastric Balloon System, featuring the Allurion Smart Capsule. We believe that FDA approval significantly increases the options available to Management going forward to support execution of its business plan. Hence, we upgrade our rating from Neutral to Buy, and establish a new price target of http://www.streetinsider.com/Analyst+Comments/Chardan+Capital+Markets+Upgrades+Allurion+Technologies+%28ALUR%29+to+Buy/26046800.html Tue, 24 Feb 2026 07:39:20 -0500 ALUR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ALLURION+TECHNOLOGIES%2C++++For%3A+Feb+23/26040272.html si-local-file:///var/storage/secattach/20260223/26040272.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ALLURION+TECHNOLOGIES%2C++++For%3A+Feb+23/26040272.html Mon, 23 Feb 2026 09:06:00 -0500 ALUR O.52535872 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ALLURION+TECHNOLOGIES%2C++++For%3A+Feb+23/26040272.html si-local-file:///var/storage/secattach/20260223/26040272.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ALLURION+TECHNOLOGIES%2C++++For%3A+Feb+23/26040272.html Mon, 23 Feb 2026 09:06:00 -0500 ALUR O.52535872 http://www.streetinsider.com/FDA/Allurion+receives+FDA+approval+for+gastric+balloon+system/26040190.html <p>Allurion Technologies Inc. (NYSE: ALUR) announced that the U.S. Food and Drug Administration has approved its premarket approval application for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule.</p> <p>The Smart Capsule is swallowed during a 15-minute office visit without surgery, endoscopy, or anesthesia. Once inside the stomach, it is filled with fluid and remains for approximately four months, occupying space to help patients feel full and eat less. After four months, a patented Release Valve opens and the capsule passes naturally from the body. A second capsule can be swallowed two months after the first passes.</p> <p>The system is approved http://www.streetinsider.com/FDA/Allurion+receives+FDA+approval+for+gastric+balloon+system/26040190.html Mon, 23 Feb 2026 09:00:40 -0500 A.06822034 A.50204046 ALUR O.00036239 O.20026344 O.52535872 http://www.streetinsider.com/FDA/Allurion+receives+FDA+approval+for+gastric+balloon+system/26040190.html <p>Allurion Technologies Inc. (NYSE: ALUR) announced that the U.S. Food and Drug Administration has approved its premarket approval application for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule.</p> <p>The Smart Capsule is swallowed during a 15-minute office visit without surgery, endoscopy, or anesthesia. Once inside the stomach, it is filled with fluid and remains for approximately four months, occupying space to help patients feel full and eat less. After four months, a patented Release Valve opens and the capsule passes naturally from the body. A second capsule can be swallowed two months after the first passes.</p> <p>The system is approved http://www.streetinsider.com/FDA/Allurion+receives+FDA+approval+for+gastric+balloon+system/26040190.html Mon, 23 Feb 2026 09:00:40 -0500 A.06822034 A.50204046 ALUR O.00036239 O.20026344 O.52535872